Dyne Q2 net loss $65.1M, cash $778.8M; ACHIEVE/DELIVER data positive

Dyne Therapeutics, Inc.

2024-Q2 EPS reported -$1.51

Q2 2024 net loss $65.1M ($0.70/sh) vs $64.9M ($1.08/sh) in Q2 2023.
Cash, cash equivalents and marketable securities $778.8M, funded at least into H2 2026.
Completed $374.3M public offering (12.075M shares at $31.00) in May 2024.
DYNE-101 in DM1 showed splicing correction and functional improvement; DYNE-251 in DMD showed dystrophin expression exceeding eteplirsen at 6 months.
Company plans to provide registration path update for both programs by year-end 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.